scholarly journals PCOS and Hyperprolactinemia: what do we know in 2019?

2019 ◽  
Vol 13 ◽  
pp. 117955811987192 ◽  
Author(s):  
Clémence Delcour ◽  
Geoffroy Robin ◽  
Jacques Young ◽  
Didier Dewailly
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Current Knowledge ◽  
Polycystic Ovary ◽  
Pcos Patient ◽  
Patient Needs ◽  
Ovary Syndrome ◽  
Imaging Methods ◽  
Endocrine Diseases ◽  
Diagnosis Criteria ◽  
Permanent Increase

Polycystic ovary syndrome (PCOS) and hyperprolactinemia (HPRL) are the two most common etiologies of anovulation in women. Since the 1950s, some authors think that there is a pathophysiological link between PCOS and HPRL. Since then, many authors have speculated about the link between these two endocrine entities, but no hypothesis proposed so far could ever be confirmed. Furthermore, PCOS and HPRL are frequent endocrine diseases and a fortuitous association cannot be excluded. The evolution of knowledge about PCOS and HPRL shows that studies conducted before the 2000s are obsolete given current knowledge. Indeed, most of the studies were conducted before consensual diagnosis criteria of PCOS and included small numbers of patients. In addition, the investigation of HPRL in these studies relied on obsolete methods and did not look for the presence of macroprolactinemia. It is therefore possible that HPRL that has been attributed to PCOS corresponded in fact to macroprolactinemia or to pituitary microadenomas of small sizes that could not be detected with the imaging methods of the time. Recent studies that have conducted a rigorous etiological investigation show that HPRL found in PCOS correspond either to non-permanent increase of prolactin levels, to macroprolactinemia or to other etiologies. None of this recent study found HPRL related to PCOS in these patients. Thus, the link between PCOS and HPRL seems to be more of a myth than a well-established medical reality and we believe that the discovery of an HPRL in a PCOS patient needs a standard etiological investigation of HPRL.

scholarly journals Molecular Mechanisms of Insulin Resistance in Polycystic Ovary Syndrome: Unraveling the Conundrum in Skeletal Muscle?

2019 ◽  
Vol 104 (11) ◽  
pp. 5372-5381 ◽  
Author(s):  
Nigel K Stepto ◽  
Alba Moreno-Asso ◽  
Luke C McIlvenna ◽  
Kirsty A Walters ◽  
Raymond J Rodgers
Keyword(s):  
Insulin Resistance ◽  
Skeletal Muscle ◽  
Polycystic Ovary Syndrome ◽  
Molecular Mechanisms ◽  
Current Knowledge ◽  
Polycystic Ovary ◽  
Evidence Synthesis ◽  
Basic Research ◽  
Future Research ◽  
Ovary Syndrome

Abstract Context Polycystic ovary syndrome (PCOS) is a common endocrine condition affecting 8% to 13% of women across the lifespan. PCOS affects reproductive, metabolic, and mental health, generating a considerable health burden. Advances in treatment of women with PCOS has been hampered by evolving diagnostic criteria and poor recognition by clinicians. This has resulted in limited clinical and basic research. In this study, we provide insights into the current and future research on the metabolic features of PCOS, specifically as they relate to PCOS-specific insulin resistance (IR), that may affect the most metabolically active tissue, skeletal muscle. Current Knowledge PCOS is a highly heritable condition, yet it is phenotypically heterogeneous in both reproductive and metabolic features. Human studies thus far have not identified molecular mechanisms of PCOS-specific IR in skeletal muscle. However, recent research has provided new insights that implicate energy-sensing pathways regulated via epigenomic and resultant transcriptomic changes. Animal models, while in existence, have been underused in exploring molecular mechanisms of IR in PCOS and specifically in skeletal muscle. Future Directions Based on the latest evidence synthesis and technologies, researchers exploring molecular mechanisms of IR in PCOS, specifically in muscle, will likely need to generate new hypothesis to be tested in human and animal studies. Conclusion Investigations to elucidate the molecular mechanisms driving IR in PCOS are in their early stages, yet remarkable advances have been made in skeletal muscle. Overall, investigations have thus far created more questions than answers, which provide new opportunities to study complex endocrine conditions.

Clinical and Hormonal Profile of Polycystic Ovary Syndrome

2009 ◽  
Vol 1 (2) ◽  
pp. 22-25
Author(s):  
Ferdousi Begum
Keyword(s):  
Menstrual Cycle ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Serum Insulin ◽  
Pcos Patient ◽  
Serum Prolactin ◽  
Transvaginal Sonography ◽  
Ovary Syndrome ◽  
Cross Sectional ◽  
Hormonal Profile

ABSTRACT Objectives The objectives of the study were to find out the clinical features, biochemical and hormonal profile of patients with polycystic ovary syndrome (PCOS) in Bangladesh. Material and Methods A case control and cross-sectional study was undertaken among 78 PCOS patients attending infertility clinic and 33 controls at BIRDEM Hospital, Dhaka. Inclusion criteria for cases were oligo/amenorrhea, transvaginal sonography suggesting PCO and/ or features of hyperandrogenemia with exclusion of other causes. Controls were women with regular menstrual cycle. Results Age and height of cases and controls were similar. BMI >25 was 67% among cases and 19% among controls (P<0.001); waist hip ratio >0.8 was 64% among cases and 29% among controls (P<0.001). Mean BMI of cases was 28.2 + 4.5 and that of cases was 21.05 + 4.1; mean fasting glucose among cases was 5.93 + 1.08 and among controls was 4.4 + 1.11 mmol/L (P<0.01); mean fasting serum insulin level was 32.15+ 12.13 among cases was 11.32 +10.02 ìU/ml among controls(P<.001); insulin resistance (fasting HOMA-IR>6.8) was 42.32% in cases and 12% in control (P<.001). Patients with PCOS had following clinical and biochemical parameters: oligomenorrhea- 74%, amenorrhea- 26%, mean Ferriman-Galaway score -19.89 + 5.06. At day 3 of menstrual cycle meanserum LH was 12.79+7.1 mmol/L, serum FSH was 5.23 + 2.5 miu/ml and serum prolactin was 415.15+180.5 mmol/L; 30% had biochemical hyperandrogenemia. Conclusions PCOS patient in Bangladesh are usually overweight, hirsute (grade I and II), hyperandrogenemic, insulin resitant and have altered LH to FSH ratio.

scholarly journals Correlation between Iron Status Parameters and Hormone Levels in Women with Polycystic Ovary Syndrome

2012 ◽  
Vol 5 ◽  
pp. CMWH.S8780 ◽  
Author(s):  
Hussein Kadhem Al-Hakeim
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Current Knowledge ◽  
Polycystic Ovary ◽  
Iron Status ◽  
Endocrine System ◽  
Serum Testosterone ◽  
Iron Store ◽  
Ovary Syndrome ◽  
Iron Stores ◽  
Body Iron Store

Much research has shown that iron store parameters are increased in women with polycystic ovary syndrome (PCOS), but an exact explanation for this phenomenon remains unavailable. The objective of this study was to investigate the correlation between iron status parameters and hormonal disturbances in women with PCOS that accounts for their increased iron store levels. Iron status parameters and hormones were measured using colorimetric and enzyme-linked immunosorbent assays, respectively. The results demonstrated a mild iron overload in the patients with PCOS. Good positive correlations between iron status parameters and serum testosterone, prolactin, and insulin were detected in the patient group, whereas iron status parameters and BMI were not significantly correlated. The data also suggest that the increase in serum ferritin and body iron store levels in patients with PCOS are associated with hyperandrogenemia, hyperprolactinemia, and hyperinsulinemia. The findings of this study expand current knowledge on the factors affecting iron stores and suggest a different mechanism of interaction between iron stores and the endocrine system through the harmful deposition of iron in endocrine glands and through hormonal effects on iron absorption and metabolism.

scholarly journals Selenium and Polycystic Ovary Syndrome; Current Knowledge and Future Directions: A Systematic Review

2019 ◽  
Vol 51 (05) ◽  
pp. 279-287 ◽  
Author(s):  
Fatemeh Hajizadeh-Sharafabad ◽  
Jalal Moludi ◽  
Helda Tutunchi ◽  
Ehsaneh Taheri ◽  
Azimeh Izadi ◽  
...  
Keyword(s):  
Systematic Review ◽  
Insulin Resistance ◽  
Polycystic Ovary Syndrome ◽  
Current Knowledge ◽  
Polycystic Ovary ◽  
Therapeutic Effects ◽  
Protective Effects ◽  
Case Control Studies ◽  
Ovary Syndrome ◽  
The Impact

AbstractPolycystic ovary syndrome (PCOS), as the most common endocrine disorder in reproductive-aged women, is recognized by hyperandrogenism and insulin resistance. Selenium (Se) potentially possesses therapeutic effects on PCOS due to antioxidant and insulin-like properties. This systematic review evaluates the potential role of Se in the complications of PCOS. A systematic review was performed on published studies reporting the effects of Se on PCOS. Three major databases including PubMed, Scopus, and Google Scholar were searched until December 2018. A total of 7 human studies and two in vitro studies met the inclusion criteria. Two out of three case-control studies showed that serum Se levels tend to decrease in patients with PCOS. Of four studies that evaluated the impact of Se supplementation on insulin resistance, only one study showed protective effects of Se against insulin resistance. Two out of three studies reported the antioxidant effect of Se. Few studies investigating anti-androgenic effect of Se presented controversial results. There were three studies that evaluated the anti-hyperlipidemic effect of Se, of which two surveys indicated the lowering effects of Se on VLDL and LDL-cholesterol. The reviewed studies confirmed inverse relationships between serum Se levels and some androgenic hormones in PCOS. Se is able to attenuate insulin resistance and dyslipidemia. The available data are currently insufficient to support the protective effects of Se on PCOS.

scholarly journals Difference of Cyclooxygenase-2 (COX2) Expression in Endometrium Between Patients with Polycystic Ovary Syndrome (PCOS) and Fertile Women

2019 ◽  
Vol 01 (04) ◽  
pp. 149-153
Author(s):  
Uki Retno Budihastuti ◽  
Eriana Melinawati ◽  
Sri Sulistyowati ◽  
Abdurrahman Laqief ◽  
M. Firdinan Dekawan
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Endometrial Biopsy ◽  
Pcos Patient ◽  
Control Group ◽  
Case Group ◽  
Ovary Syndrome ◽  
Cox 2 ◽  
And Control ◽  
Fertile Women

Objective: The study was conducted to determine whether there were differences in COX-2 expression in endometrial women with PCOS compared to fertile women. Methods: This study is a case-control study investigating the relationship between exposure (research factors) and disease, by comparing case group and control group based on their exposure status. The samples of this study were infertile polycystic ovary syndrome patients who were treated at the Sekar Fertility Clinic in Dr. Moewardi Hospital Surakarta, and fertile women seeking treatment at Dr. Moewardi Hospital Surakarta. The number of samples were 60 subjects consisting of 30 PCOS patients and 30 fertile women. The expression of COX-2 in endometrial biopsy LH + 5 until LH + 10 which meet the inclusion with Rotterdam criteria and exclusion criteria was checked by immunohistochemistry. The data was analyzed using the Mann-Whitney test. Results: The mean COX-2 expression in PCOS (10.83 ± 5.35) in fertile women (37.00 ± 7.76), p = 0.005. Regression test of COX-2 by adjusting external variables (occupation, age, education, menstrual disorders, familial history, menstrual cycle, menarche, obesity, contraception history) shows also higher expression in PCOS patient with OR = -7.063; CI = 0.462–108.066; p = 0.160. Conclusion: COX-2 expression in endometrium of women with PCOS is lower than it is in fertile women.

scholarly journals Research Progress on the Mechanism Between Polycystic Ovary Syndrome and Abnormal Endometrium

2021 ◽  
Vol 12 ◽  
Author(s):  
Zhu Xue ◽  
Juanli Li ◽  
Jiaxing Feng ◽  
Han Han ◽  
Jing Zhao ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Embryo Implantation ◽  
Pcos Patient ◽  
Research Progress ◽  
Ovary Syndrome ◽  
Increased Risk ◽  
17Β Estradiol ◽  
Reproductive Aged Women

As a highly dynamic tissue, the endometrium is periodically shed in response to the secretion of estrogen and progesterone. After menarche, the endometrium of healthy women proliferates and differentiates under the action of steroid hormones (e.g., 17β-estradiol and progesterone) that are secreted by the ovaries to provide appropriate conditions for embryo implantation. Polycystic ovary syndrome (PCOS), a prevalent endocrine and metabolic disorder in reproductive-aged women, is usually associated with multiple cysts within the ovaries and excess levels of androgen and is characterized by hirsutism, acne, menstrual irregularity, infertility, and increased risk of insulin resistance. Multiple factors, such as anovulation, endocrine-metabolic abnormalities, and inflammation, can disrupt the endometrium in PCOS patients and can lead to endometrial hyperplasia, pregnancy complications, or even cancer. Despite many recent studies, the relationship between PCOS and abnormal endometrial function is still not fully understood. In this review, we investigate the correlation of PCOS patient endometrium with anovulation, hyperandrogenemia, insulin resistance, progesterone resistance, and inflammatory cytokines, aiming to provide a theoretical basis for the treatment of disorders caused by endometrial dysfunction in PCOS patients.

Sign in / Sign up

Export Citation Format

Share Document